glp-1 muscle loss prevention and Loss: Semaglutide, Tirzepatide & Lean Mass Long-term Success of GLP-1s Hinges

Nauck MA, Quast DR, Wefers J, Pfeiffer AFH (2021) The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update

Growth hormone secretion from the anterior pituitary gland is controlled by two primary opposing signals: Growth hormone-releasing hormone (GHRH): Produced by the hypothalamus, GHRH stimulates GH synthesis and release from pituitary somatotroph cells Somatostatin: Also produced by the hypothalamus, somatostatin inhibits GH release, creating a pulsatile pattern of secretion A third regulatory pathway involves ghrelin and growth hormone secretagogues (GHS) , which act through a separate receptor system (GHS-R1a) to amplify GH release independently of GHRH (1)

It does not provide medical advice, recommend doses, prescribe medication, create protocols, or replace instructions from a licensed healthcare professional or medication label

Ideal for People Who Are starting or currently using GLP-1 medications such as semaglutide or tirzepatide Want structured nutrition without tracking or cooking Struggle to meet protein or fiber needs with reduced appetite Prefer meals aligned with established nutrition guidelines Nutrition That Fits Into Real Life GLP-1 medications change how much you want to eat not how important nutrition is

Clinical evidence indicating accelerated antidepressant response, improved cognition, enhanced sleep architecture, and reduced biomarkers of neuronal injury in elderly and medically comorbid populations underscores its relevance in late-life depression and depression associated with cognitive or vascular dysfunction (96)